Personalised therapeutic cancer vaccine cuts risk of melanoma recurrence, opening door to new era of cancer treatment
In a world-first international trial, adding a therapeutic cancer vaccine to standard immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.
Pooled analysis of five-year survival: neoadjuvant immunotherapy for melanoma translates to real-world care
An international pooled study led by Professor Georgina Long AO, and published in Nature Medicine, showed patients whose tumours responded well to neoadjuvant immunotherapy had outstanding 5-year survival.